Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: A potential long-acting glucagon-like peptide-1 mimetic

BMB Reports

Volumn 43, Issue 2, 2010, Pages 146-150

  Kim, Jae Woo ^a   Kim, Kyutae ^a   Ahn, Youjin ^b   Jeong, Heejeong ^b   Jeong, Hyeongyong ^b   Ryu, Seunghyup ^b   Lee, Seungyeon ^b   Lee, ChangWoo ^a   Chung, Hye Shin ^c   Jang, Sei Heon ^a  

^a Daegu University   (South Korea)

^b Gyeongsan Science High School   (South Korea)

^c Hannam University   (South Korea)

Author keywords

Exendin 4; Glucagon like peptide 1; Insulin receptor substrate 2; Type 2 diabetes

Indexed keywords

ESCHERICHIA COLI; HELODERMATIDAE; RATTUS; SQUAMATA;

ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; INSULIN RECEPTOR SUBSTRATE; PEPTIDE; VENOM;

ANIMAL; ARTICLE; ESCHERICHIA COLI; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; ESCHERICHIA COLI; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; PEPTIDES; RATS; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS; VENOMS;

EID: 77952502739     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/bmbrep.2010.43.2.146     Document Type: Article

References (16)

1. Eng, J., Kleinman, W. A., Singh, L., Singh, G. and Raufman, J. P. (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267, 7402-7405.
2. Hui, H., Nourparvar, A., Zhao, X. and Perfetti, R. (2003) Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A-and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144, 1444-1455.
3. Xu, G., Stoffers, D. A., Habener, J. F. and Bonner-Weir, S. (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-2276.
4. Deacon, C. F., Johnsen, A. H. and Holst, J. J. (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952-957.
5. Giannoukakis, N. (2003) Exenatide. Amylin/Eli Lilly. Curr. Opin. Investig. Drugs. 4, 459-465.
6. Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E. and Maggs, D. G. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275-286.
7. Schmidt, S. R. (2009) Fusion-proteins as biopharmaceuticals - applications and challenges. Curr. Opin. Drug. Discov. Devel. 12, 284-295.
8. Kumar, M., Hunag, Y., Glinka, Y., Prud'homme, G. J. and Wang, Q. (2007) Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther. 14, 162-172.
9. Kim, D. M., Chu, S. H., Kim, S., Park, Y. W. and Kim, S. S. (2009) Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation. BMB Rep. 42, 212-216.
10. Soltani, N., Kumar, M., Glinka, Y., Prud'homme, G. J. and Wang, Q. (2007) In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther. 14, 981-988.
11. Huang, Y. S., Chen, Z., Chen, Y. Q., Ma, G. C., Shan, J. F., Liu, W. and Zhou, L. F. (2008) Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J. Pept. Sci. 14, 588-595.
12. Park, S., Dong, X., Fisher, T. L., Dunn, S., Omer, A. K., Weir, G. and White, M. F. (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 281, 1159-1168.
13. Jhala, U. S., Canettieri, G., Screaton, R. A., Kulkarni, R. N., Krajewski, S., Reed, J., Walker, J., Lin, X., White, M. and Montminy, M. (2003) cAMP promotes pancreatic b-cell survival via CREB-mediated induction of IRS2. Genes Dev. 17, 1575-1580.
14. White, M. F. (2003) Insulin signaling in health and disease. Science 302, 1710-1711.
15. Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K. and Young, A., (2001) Pharmaco-kinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug. Dev. Res. 54, 260-267.
16. Leahy, D. J., Dann, C. E., 3rd, Longo, P., Perman, B. and Ramyar, K. X. (2000) A mammalian expression vector for expression and purification of secreted proteins for structural studies. Protein Expr. Purif. 20, 500-506.